R

    Rhythm Pharmaceuticals Inc (RYTM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $106.13
    -1.04 (-0.97%)

    Market Cap: $7.38B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(23/36)
    Avg Surprise
    -14.46%
    Streak
    3 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.75
    Range$-0.85 - $-0.67
    11 analysts
    EPS Revisions
    6
    0
    7d
    5
    3
    30d
    EPS Estimate Drift
    90d ago$-0.83-10.0%
    60d ago$-0.83-9.8%
    30d ago$-0.83-10.1%
    7d ago$-0.75+0.0%
    Current$-0.75
    Revenue Consensus
    $84M
    Range$78M - $93M
    15 analysts
    Dec 31, 2026
    EPS Consensus$-0.62
    Range$-0.91 - $-0.38
    11 analysts
    Revenue Consensus
    $106M
    Range$92M - $129M
    15 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.62---
    Sep 26EST
    		-$-0.75---
    Jun 26
    		$-0.73$-0.81+9.88%Beat+2.7%
    Mar 26
    		$-0.83$-0.86+3.49%Beat-2.5%
    Dec 25
    		$-0.73$-0.79+7.59%Beat-1.4%
    Sep 25
    		$-0.82$-0.73-12.33%Miss-12.3%
    Jun 25
    		$-0.75$-0.67-11.94%Miss-36.4%
    Mar 25
    		$-0.81$-0.68-19.12%Miss+65.5%
    Dec 24
    		$-0.72$-0.73+1.37%Beat-2.9%
    Sep 24
    		$-0.73$-0.87+16.09%Beat+3.9%
    Jun 24
    		$-0.55$-0.72+23.61%Beat+32.9%
    Mar 24
    		$-2.35$-2.39+1.67%Beat-155.4%
    Dec 23
    		$-0.70$-0.70+0.00%Beat+6.7%
    Sep 23
    		$-0.76$-0.76+0.00%Beat+3.8%
    Jun 23
    		$-0.82$-0.78-5.13%Miss+7.9%
    Mar 23
    		$-0.92$-0.77-19.48%Miss+12.4%
    Dec 22
    		$-0.75$-0.81+7.41%Beat+11.8%
    Sep 22
    		$-0.79$-0.98+19.39%Beat-12.9%
    Jun 22
    		$-0.89$-1.03+13.59%Beat-27.1%
    Mar 22
    		$-1.05$-1.04-0.96%Miss+9.5%
    Dec 21
    		$-0.85$-0.91+6.59%Beat-7.6%
    Sep 21
    		$-0.70$-0.83+15.66%Beat+9.1%
    Jun 21
    		$-0.70$-0.74+5.41%Beat+1.4%
    Mar 21
    		$-1.16$0.30-486.67%Miss-48.7%
    Dec 20
    		$-0.79$-0.79+0.00%Beat-1.3%
    Sep 20
    		$-0.77$-0.80+3.75%Beat+26.0%
    Jun 20
    		$-0.71$-0.82+13.41%Beat+42.7%
    Mar 20
    		$-0.78$-0.82+4.88%Beat+7.1%
    Dec 19
    		$-0.78$-0.89+12.36%Beat-5.4%
    Sep 19
    		$-1.04$-1.10+5.45%Beat-100.0%
    Jun 19
    		$-1.24$-0.85-45.88%Miss-138.5%
    Mar 19
    		$-0.84$-0.73-15.07%Miss-40.0%
    Dec 18
    		$-0.74$-0.57-29.82%Miss-80.5%
    Sep 18
    		$-0.52$-0.61+14.75%Beat+21.2%
    Jun 18
    		$-0.52$-0.47-10.64%Miss-26.8%
    Mar 18
    		$-0.60$-0.42-42.86%Miss-106.9%
    Dec 17
    		$-0.41$-0.46+10.87%Beat-
    Sep 17
    		$-0.66$-0.56-17.86%Miss-
    Jun 17
    		$-0.41$0.00N/AMiss-
    Mar 17
    		$-0.29$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-34.13EV/EBITDA-12.65x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-85.60%Operating Margin-68.10%
    ROE-117.10%ROIC-96.13%
    Financial Health
    Debt/Equity1.03xInterest Coverage-10.88x
    Current Ratio3.45xQuick Ratio3.20x
    Trading Statistics
    Beta1.97Avg Volume648.16K
    52-Week High$122.2052-Week Low$74.50

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$111.24
    SMA 20$112.47
    SMA 50$109.62
    SMA 200$99.47
    EMA 10$110.52
    EMA 20$110.75
    EMA 50$107.48
    EMA 200$98.25

    MACD

    Line: 0.43Signal: 1.49Hist: -1.06

    ADX

    ADX: 18.5+DI: 13.8-DI: 25.0

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down24.0
    PSAR$116.72

    Bollinger Bands

    Upper Band$119.46
    Lower Band$105.49
    %B Position1241%(Upper)
    Band Width0.05

    RSI (14-Day)

    Neutral
    42.7

    Momentum Oscillators

    Stoch %K21.1
    Stoch %D32.2
    Williams %R-86.4
    ROC (10d)-8.1%
    Momentum-9.31
    CCI (20d)-146.1
    MFI (14d)47.3

    Volatility Measures

    ATR (14d)$4.72(4.5%)
    StdDev (20d)3.49
    Hist Vol41.9%(High)

    Volume Flow

    VWAP$106.32
    OBV32.0M
    AD Line12.1M
    CMF (20d)0.075

    Volume Metrics

    Avg Vol (20d)632.4K
    Vol Ratio1.1x
    VWMA (20d)$111.87

    Pivot Points

    R3$119.91
    R2$117.33
    R1$112.25
    Pivot Point$109.67
    S1$104.59
    S2$102.01
    S3$96.93

    Advanced Oscillators

    TSI3.15
    Ultimate Osc39.4
    KST32.53

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$71.25M$60.11M$57.25M$51.30M$48.50M$32.70M$41.83M$33.25M$29.08M$25.97M$24.23M$22.50M
    Cost of Revenue$8.93M$7.16M$4.80M$5.50M$5.54M$3.65M$3.79M$3.83M$2.95M$2.81M$3.23M$2.41M
    Gross Profit$62.32M$52.95M$52.45M$45.80M$42.96M$29.06M$38.04M$29.42M$26.13M$23.16M$21.00M$20.09M
    Operating Expenses$110.88M$105.32M$99.51M$98.45M$88.25M$76.06M$79.30M$73.31M$66.61M$163.05M$62.27M$64.05M
    R&D$43.43M$41.73M$42.03M$46.03M$42.31M$36.97M$41.17M$37.93M$30.19M$128.66M$29.89M$33.57M
    SG&A$67.45M$63.59M$57.48M$52.42M$45.95M$39.09M$38.13M$35.38M$36.41M$34.38M$32.38M$30.48M
    Operating Income$-48,552,000$-52,361,000$-47,063,000$-52,653,000$-45,296,000$-47,004,000$-41,253,000$-43,885,000$-40,478,000$-139,887,000$-41,269,000$-43,953,000
    Interest Income$3.22M$3.55M$4.08M$4.33M$3.24M$3.64M$3.51M$4.05M$4.10M$3.05M$3.82M$3.47M
    Interest Expense$4.54M$4.58M$4.62M$4.74M$5.82M$5.41M$6.00M$5.24M$4.60M$4.75M$4.38M$3.15M
    Income Before Tax$-48,854,000$-55,094,000$-47,536,000$-52,793,000$-46,295,000$-49,418,000$-43,417,000$-43,985,000$-31,782,000$-141,072,000$-41,437,000$-43,795,000
    Income Tax Expense$444,000$545,000$-31,000$111,000$337,000$80,000$-89,000$-344,000$479,000$300,000$196,000$368,000
    Net Income$-49,298,000$-55,639,000$-47,505,000$-52,904,000$-46,632,000$-49,498,000$-43,328,000$-43,641,000$-32,261,000$-141,372,000$-41,633,000$-44,163,000
    EBITDA$-48,457,000$-55,249,000$-48,588,000$-53,770,000$-44,520,000$-49,052,000$-42,683,000$-44,877,000$-33,078,000$-140,328,000$-50,294,000$-39,371,000
    EBIT$-47,534,000$-54,065,000$-47,005,000$-52,379,000$-43,720,000$-47,648,000$-40,928,000$-42,797,000$-31,276,000$-139,363,000$-40,876,000$-44,112,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RYTM

    News

    Rhythm Pharmaceuticals (RYTM) Stock Looks Overvalued Despite Its 7x Five Year Run

    Rhythm Pharmaceuticals (RYTM) stock, despite a sevenfold increase in its share price over the past five years, appears overvalued based on current market multiples. While the recent approval of IMCIVREE in Japan could boost future revenue, the stock's price-to-sales ratio of 32.5x significantly exceeds the biotech industry average, suggesting it has run too far on sales. The article concludes that future returns will depend on the company's ability to convert its pipeline and approvals into sustained commercial success without significant setbacks.

    Yahoo Finance•8/26/26•
    Somewhat-Bearish

    Rhythm Pharmaceuticals (RYTM) Could Be 15% Undervalued As Japan Approval Lifts Its Story

    Rhythm Pharmaceuticals (RYTM) has seen increased attention after Japan approved IMCIVREE for acquired hypothalamic obesity, bolstering its stock performance. Despite a 15.4% undervaluation narrative suggesting a fair value of $134, the company's current P/S ratio of 32.5x is significantly higher than industry averages, indicating potential valuation risk. Investors are advised to scrutinize the growth story against the premium valuation.

    Simply Wall Street•8/26/26•
    Bullish

    Rhythm's Imcivree becomes first approved therapy for acquired hypothalamic obesity in Japan

    Rhythm Pharmaceuticals' Imcivree (setmelanotide) has received marketing authorization in Japan for acquired hypothalamic obesity (HO), making it the first approved therapy for this condition in the country. The approval is based on the Phase III TRANSCEND trial, which showed a significant reduction in BMI. Rhythm expects to launch the drug before the end of 2026 and estimates 5,000 to 8,000 patients in Japan could benefit.

    AllSci•8/25/26•
    Bullish

    Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE®

    Rhythm Pharmaceuticals announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved IMCIVREE® (setmelanotide) for patients with acquired hypothalamic obesity (HO). This makes IMCIVREE the first approved therapy in Japan for this condition, which is estimated to affect 5,000 to 8,000 people in the country. Rhythm expects to launch the treatment by the end of 2026, following pricing determination, with the approval supported by positive Phase 3 trial data.

    GlobeNewswire•8/25/26•
    Bullish

    Rhythm Pharmaceuticals gains Japan approval for obesity therapy

    Rhythm Pharmaceuticals received Japanese marketing authorization for its IMCIVREE therapy, an obesity treatment for acquired hypothalamic obesity, targeting 5,000 to 8,000 people in Japan. This approval followed a successful Phase 3 TRANSCEND trial showing an 18.8% reduction in BMI. The company plans to officially launch the therapy in Japan by the end of 2026, pending final pricing agreements.

    grafa.com•8/24/26•
    Bullish

    Frequently Asked Questions About RYTM

    Does RYTM pay dividends?
    Rhythm Pharmaceuticals Inc (RYTM) does not currently pay a regular dividend.
    What is RYTM's market cap?
    Rhythm Pharmaceuticals Inc (RYTM) has a market capitalization of $7.38B with a current stock price of $106.13.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In